# Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

> **NCT00123591** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 96 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Trauma

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00123591
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123591, "Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00123591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*